Congenital heart disease (CHD) is the most common survivable birth defect, affecting 0.7% of all liveborn infants worldwide. Management of CHD has made great strides, so that there are now more living adults with CHD than children, but many patients with complex CHD have long-term morbidity frequently manifesting as neurodevelopmental abnormalities (NDA). The causative mechanisms of CHD have been poorly understood although genetic factors are strongly believed to play a role. Dramatic advances in genomic technologies now allow systematic identification of specific genes and pathways that have very large effects on disease pathogenesis. As part of the PCGC, we have performed whole-exome sequencing on 1,300 parent-offspring trios selected from over 9,000 patients recruited into the PCGC study. The salient findings are that de novo mutations occurring in genes that are highly expressed in the heart account for at least 8% of the CHD cases studied, and disproportionately occur in patients with CHD classified as left ventricular outflow obstruction, and in patients with CHD and NDA. Among the genes with de-novo mutations in CHD there is a marked enrichment of mutations, particularly damaging mutations, in genes involved in chromatin modification, and these mutations are strongly biased toward CHD cases with NDA. Moreover, and very unexpectedly, we find highly significant overlap of genes with damaging mutations in CHD and in autism. We propose that genes involved in chromatin regulation are dosage sensitive for both heart and neurodevelopment, and that mutations in these genes can result in both CHD and NDA. By sequencing all genes in the chromatin modification set in 10,000 PCGC cases using rapid, inexpensive targeted sequencing via MIPS (molecular inversion probe sequencing) we will identify genes in this pathway that contribute to CHD and determine their specific relationship to NDA. Since the last funding cycle has enabled us to show that CHD has high locus heterogeneity, we will also continue to use cost-effective exome sequencing to identify additional genes in which de-novo mutations confer large effects on disease risk. In order to determine the spectrum of NDA resulting from chromatin modifier mutations, we will identify patients from the existing PCGC cohort with and without mutation in this gene set and perform neurodevelopmental testing. Finally, we will prospectively recruit patients under one year of age, test for chromatin modifier mutations, and follow their neurodevelopmental outcome. In summary, we expect these studies to identify an easily testable set of genes that can be evaluated rapidly and inexpensively to identify CHD patients at increased risk for ND abnormalities.

Public Health Relevance

A genetic abnormality is thought to underlie a substantial portion of CHD, but the identity of the abnormalities has not been identified in 70% of affected patients. This proposal seeks to apply state-of-the-art genomic technology to a large cohort of CHD patients recruited as part of the PCGC program to identify the genetic cause of CHD, and then to link the genetic findings to neurodevelopmental outcome in patients with CHD. (End of Abstract)

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1HL098162-11
Application #
9751921
Study Section
Special Emphasis Panel (ZHL1)
Program Officer
Kaltman, Jonathan R
Project Start
2009-09-30
Project End
2020-07-31
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
11
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Yale University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Manheimer, Kathryn B; Patel, Nihir; Richter, Felix et al. (2018) Robust identification of deletions in exome and genome sequence data based on clustering of Mendelian errors. Hum Mutat 39:870-881
Martinelli, Simone; Krumbach, Oliver H F; Pantaleoni, Francesca et al. (2018) Functional Dysregulation of CDC42 Causes Diverse Developmental Phenotypes. Am J Hum Genet 102:309-320
Zaidi, Samir; Brueckner, Martina (2017) Genetics and Genomics of Congenital Heart Disease. Circ Res 120:923-940
Simmons, M Abigail; Brueckner, Martina (2017) The genetics of congenital heart diseaseā€¦ understanding and improving long-term outcomes in congenital heart disease: a review for the general cardiologist and primary care physician. Curr Opin Pediatr 29:520-528
Jin, Sheng Chih; Homsy, Jason; Zaidi, Samir et al. (2017) Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probands. Nat Genet 49:1593-1601
McKean, David M; Homsy, Jason; Wakimoto, Hiroko et al. (2016) Loss of RNA expression and allele-specific expression associated with congenital heart disease. Nat Commun 7:12824
Homsy, Jason; Zaidi, Samir; Shen, Yufeng et al. (2015) De novo mutations in congenital heart disease with neurodevelopmental and other congenital anomalies. Science 350:1262-6
Backenroth, Daniel; Homsy, Jason; Murillo, Laura R et al. (2014) CANOES: detecting rare copy number variants from whole exome sequencing data. Nucleic Acids Res 42:e97
Glessner, Joseph T; Bick, Alexander G; Ito, Kaoru et al. (2014) Increased frequency of de novo copy number variants in congenital heart disease by integrative analysis of single nucleotide polymorphism array and exome sequence data. Circ Res 115:884-896
Pediatric Cardiac Genomics Consortium; Gelb, Bruce; Brueckner, Martina et al. (2013) The Congenital Heart Disease Genetic Network Study: rationale, design, and early results. Circ Res 112:698-706